表达CD30和CD15的外周T细胞淋巴瘤扩展了ALK阴性间变性大细胞淋巴瘤的谱系
该研究分析19例外周T细胞淋巴瘤(PTCL)病例,其中9例既往诊断为ALK阴性间变性大细胞淋巴瘤(ALCL, ALK-),10例为CD30和CD15共表达的PTCL(PTCL CD30+CD15+),采用NanoString nCounter平台进行DUSP22/IRF4重排、编码RNA表达和转录组分析。无监督聚类显示ALCL, ALK-与PTCL CD30+CD15+之间无清晰分离,3例既往分类为PTCL CD30+CD15+的病例存在DUSP22/IRF4重排,支持ALCL, ALK-诊断。结果提示PTCL CD30+CD15+可能落在ALCL, ALK-谱系内,且部分伴DUSP22/IRF4重排的ALCL, ALK-表达CD15,扩展了该淋巴瘤亚群的免疫表型谱。
要点
- 19例PTCL中9例为ALCL, ALK-,10例为PTCL CD30+CD15+,无监督聚类未见两者清晰分离。
- 3例既往分类为PTCL CD30+CD15+的病例检出DUSP22/IRF4重排,支持ALCL, ALK-诊断。
- 部分伴DUSP22/IRF4重排的ALCL, ALK-表达CD15,扩展了该亚群免疫表型谱。
核心结论
- 既往 designated 为PTCL CD30+CD15+的病例可能落在ALCL, ALK-谱系内。
- 部分伴DUSP22/IRF4重排的ALCL, ALK-表达CD15,与既往报道一致并扩展了该淋巴瘤亚群的免疫表型谱。
研究设计与样本
- 分析19例PTCL病例,其中既往诊断为ALCL, ALK-者9例、PTCL CD30+CD15+者10例。
- 采用NanoString nCounter基因表达分析平台进行DUSP22/IRF4重排、编码RNA表达和选定转录组分析。
主要发现
- 无监督聚类显示ALCL, ALK-与PTCL CD30+CD15+之间无清晰分离。
- 3例既往分类为PTCL CD30+CD15+的病例显示DUSP22/IRF4重排,支持ALCL, ALK-诊断。
- 部分伴DUSP22/IRF4重排的ALCL, ALK-表达CD15。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peripheral T-cell lymphomas (PTCL) are morphologically and biologically heterogeneous and a subset expresses CD30, including anaplastic large cell lymphomas (ALCL) and a minority of PTCL, not otherwise specified (PTCL, NOS). ALCL with ALK translocations (ALCL, ALK+) are readily identified by routine diagnostic methods, but differentiating ALCL without ALK translocation (ALCL, ALK-) and PTCL, NOS expressing CD30 (PTCL CD30+) can be challenging. Furthermore, rare PTCL co-express CD30 and CD15 (PTCL CD30+CD15+); some resemble ALCL, ALK- while others resemble classic Hodgkin lymphoma. To explore the relationship between PTCL CD30+CD15+ and ALCL, ALK-, we analysed 19 cases of PTCL with CD30 expression, previously diagnosed as ALCL, ALK- (nine cases) and PTCL CD30+CD15+ (10 cases) for DUSP22/IRF4 rearrangements, coding RNA expression and selected transcriptome analysis using the NanoString nCounter gene expression analysis platform. Unsupervised clustering showed no clear segregation between ALCL, ALK- and PTCL CD30+CD15+. Three cases previously classified as PTCL CD30+CD15+ showed DUSP22/IRF4 rearrangements, favouring a diagnosis of ALCL, ALK-. Our results suggest that cases previously designated PTCL CD30+CD15+, likely fall within the spectrum of ALCL, ALK-; additionally, a subset of ALCL, ALK- with DUSP22/IRF4 rearrangement expresses CD15, consistent with previous reports and expands the immunophenotypic spectrum of this lymphoma subgroup.
引用
- Ganapathi KA, Nicolae A, Egan C, et al. Peripheral T-cell lymphomas expressing CD30 and CD15 expand the spectrum of anaplastic large cell lymphoma, ALK-negative. Br J Haematol. 2024. PMID: 38613165. doi:10.1111/bjh.19442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。